SynthesisCancer2021
Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.
Synthesis in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessing the Potential of HPV16 E6 Seroprevalence as a Biomarker for Anal Dysplasia and Cancer Screening-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis.Journal of medical virology · 2023Pooled it
- Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2023Trial
- Integrating non-coding RNA profiling with HPV genotyping for cervical cancer risk stratification and early detection.Molecular biology reports · 2026Review
- Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence.Cancer causes & control : CCC · 2026Article
- Detection of recurrence of HPV-driven oropharyngeal cancer by HPV cell-free DNA.Scientific reports · 2026Article
- Human Papillomavirus: Update in Bridging Basic Science to Clinical and Public Health Innovations.Health science reports · 2026Article
- Integrating Biomarkers into Cervical Cancer Screening-Advances in Diagnosis and Risk Prediction: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Process Mapping to Compare and Improve Management of Abnormal Cervical Cancer Screening Results in Two US Healthcare Systems within the PROSPR Consortium.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Unlocking the Interactions Between the Whole-Body Microbiome and HPV Infection: A Literature Review.Pathogens (Basel, Switzerland) · 2025Review
- Serum profiling of the antibody response to HPV in women with or without abnormal cervical cytology undergoing cervical cancer screening.Frontiers in immunology · 2025Article
- Understanding and treating HPV-associated oropharyngeal carcinoma: insights from a MedNewsWeek Keynote lecture by Dr Theodoros N. Teknos and literature review.Therapeutic advances in medical oncology · 2025Review
- Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening.Cancer biomarkers : section A of Disease markers · 2025Article
- Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.Cancers · 2024Review
- HPV-associated cervicovaginal microbiome and host metabolome characteristics.BMC microbiology · 2024Article
- Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker.Cancer cell international · 2023Review
- Clinical data, survival, and prognosis of 426 cases of oropharyngeal cancer: a retrospective analysis.Clinical oral investigations · 2023Article
- Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory.Journal of clinical microbiology · 2023Review
- Human Papilloma Virus: An Unraveled Enigma of Universal Burden of Malignancies.Pathogens (Basel, Switzerland) · 2023Review
- T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundDespite the significant societal burden of human papillomavirus (HPV)-associated cancers, clinical screening interventions for HPV-associated noncervical cancers are not available. Blood-based biomarkers may help close this gap in care.
methodsFive databases were searched, 5687 articles were identified, and 3631 unique candidate titles and abstracts were independently reviewed by 2 authors; 702 articles underwent a full-text review. Eligibility criteria included the assessment of a blood-based biomarker within a cohort or case-control study.
resultsOne hundred thirty-seven studies were included. Among all biomarkers assessed, HPV-16 E seropositivity and circulating HPV DNA were most significantly correlated with HPV-associated cancers in comparison with cancer-free controls. In most scenarios, HPV-16 E6 seropositivity varied nonsignificantly according to tumor type, specimen collection timing, and anatomic site (crude odds ratio [cOR] for p16+ or HPV+ oropharyngeal cancer [OPC], 133.10; 95% confidence interval [CI], 59.40-298.21; cOR for HPV-unspecified OPC, 25.41; 95% CI, 8.71-74.06; cOR for prediagnostic HPV-unspecified OPC, 59.00; 95% CI, 15.39-226.25; cOR for HPV-unspecified cervical cancer, 12.05; 95% CI, 3.23-44.97; cOR for HPV-unspecified anal cancer, 73.60; 95% CI, 19.68-275.33; cOR for HPV-unspecified penile cancer, 16.25; 95% CI, 2.83-93.48). Circulating HPV-16 DNA was a valid biomarker for cervical cancer (cOR, 15.72; 95% CI, 3.41-72.57). In 3 cervical cancer case-control studies, cases exhibited unique microRNA expression profiles in comparison with controls. Other assessed biomarker candidates were not valid.
conclusionsHPV-16 E6 antibodies and circulating HPV-16 DNA are the most robustly analyzed and most promising blood-based biomarkers for HPV-associated cancers to date. Comparative validity analyses are warranted. Variations in tumor type-specific, high-risk HPV DNA prevalence according to anatomic site and world region highlight the need for biomarkers targeting more high-risk HPV types. Further investigation of blood-based microRNA expression profiling appears indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.